A review of bisphosphonate-associated osteonecrosis of the jaws and its management.
Bisphosphonate-associated osteonecrosis (BON) may result in serious oral complications, such as osteomyelitis and chronic exposure of necrotic bone. Dentists must be familiar with this disorder and pay special attention to all patients on bisphosphonate therapy due to their defective osteoclast function and reduced osseous tissue vascularity, leading to impaired wound healing. The purpose of this paper is to review the history and pathogenesis of BON, discuss its differential diagnosis, provide guidance to dentists on possible measures to prevent BON and review the management of patients with BON.
Lam
David K
DK
Division of Oral and Maxillofacial Surgery and Anesthesia, Mount Sinai Hospital.
Sándor
George K B
GK
Holmes
Howard I
HI
Evans
A Wayne
AW
Clokie
Cameron M L
CM
D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D016723:Bone Remodeling / Q000187:drug effects; D024042:Collagen Type I / Q000032:analysis; D000075202:Contraindications; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000628:therapy; D018919:Neovascularization, Physiologic / Q000187:drug effects; D019647:Oral Surgical Procedures; D010020:Osteonecrosis / Q000139:chemically induced* / Q000628:therapy; D010455:Peptides / Q000032:analysis
D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide